Towards an AI-Driven CRISPR Future
SynBioBeta
|
February 11, 2025
X min read
SynBioBeta
|
February 11, 2025
Share on Social
More like this
News
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
April 28, 2025
Read Now
Press
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
April 28, 2025
Read Now
News
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
April 23, 2025
Read Now
Press
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
April 23, 2025
Read Now
